Ursodiol, an FDA-approved medication for primary biliary cirrhosis, likely enhances therapeutic efficacy by upregulating NRF2, thereby inducing detoxification and antioxidant mechanisms. Here, NFE2L2 is linked to primary biliary cholangitis.